Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for subjects on Seretide Accuhaler 250/50 µg at screening:
Inclusion criteria for subjects on equivalent /higher dose or other ICS-LABAs or higher dose of Seretide at screening:
Male and female subjects ≥18 years old.
Adequate contraception
Documented clinical history of asthma for ≥6 months prior to screening visit
R5-R20 ≥0.07 kPa/L/s as measured on impulse oscillometry during the screening visit.
Exclusion Criteria for all subjects:
Exclusion Criteria for subset of subjects undergoing OR-MRI and HD-CT
Primary purpose
Allocation
Interventional model
Masking
105 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal